Treatment for hypogonadism is on the rise, particularly in the aging population. Yet treatment in this population represents a unique challenge to clinicians. The physiology of normal aging is complex and often shares the same, often vague, symptoms of hypogonadism. In older men, a highly prevalent burden of comorbid medical conditions and polypharmacy complicates the differentiation of signs and symptoms of hypogonadism from those of normal aging, yet this differentiation is essential to the diagnosis of hypogonadism. Even in older patients with unequivocally symptomatic hypogonadism, the clinician must navigate the potential benefits and risks of treatment that are not clearly defined in older men. More recently, a greater awareness of the potential risks associated with treatment in older men, particularly in regard to cardiovascular risk and mortality, have been appreciated with recent changes in the US Food and Drug Administration recommendations for use of testosterone in aging men. The aim of this review is to provide a framework for the clinician evaluating testosterone deficiency in older men in order to identify correctly and treat clinically significant hypogonadism in this unique population while minimizing treatment-associated harm.
Introduction
Testosterone has become one of the most widely prescribed medications in the USA, increasing five-fold according to 2011 data. This increase has resulted in the dramatic growth of the testosterone replacement therapy (TRT) sector of the pharmaceutical industry from US$18 million in the 1980s to US$1.6 billion in 2011 [Handelsman, 2013] . The reason is multifactorial, but can partly be attributed to the continued growth of the population over 65 years of age and a greater awareness of medical comorbidities more prevalent with age and associated with low testosterone, such as metabolic syndrome (MetS) and cardiovascular disease (CVD) [Traish et al. 2009a [Traish et al. , 2009b .
Testosterone levels also decrease with age as rapidly as 0.4-2% annually after age 30 years [Harman et al. 2001; Kaufman and Vermeulen, 2005; Wu et al. 2008] , with 35% of men in the seventh decade having lower testosterone levels than younger men [Vermeulen and Kaufman, 1995] , and 13% of older age men meeting diagnostic levels for hypogonadism [Araujo et al. 2007; Zarotsky et al. 2014 ]. This has led to the emergence of a group of men older than age 65 years with hypogonadism deemed 'late-onset' hypogonadism (LOH) or andropause, one of many synonyms.
Accurate characterization of this group of men with LOH is particularly difficult since the symptoms of hypogonadism are often nonspecific compared with the expected symptoms of aging [McGill et al. 2012 ]. Furthermore, the benefits and risks of treatment in this group are even less defined, leading to several important controversies. The US Food and Drug Administration (FDA) issued a statement in March 2015 stating that exogenous testosterone should not be used for hypogonadism due only to aging without a 'defined cause', broadly stated as a 'disorder of the testicles, pituitary gland, or brain resulting in hypogonadism'. Such language suggests that a population of aging men with symptomatic hypogonadism due to identifiable causes exists in whom consideration for treatment is warranted. Therefore, the key to evaluation is moving away from the terminology of 'LOH' and attempting to identify whether a truly pathophysiologic issue is involved. In addition, because the risks of TRT in this population are higher than in younger men, the risk profile of TRT becomes a driving force in the decision to treat or observe. The aim of this review is to describe the pathophysiology and physical diagnosis of symptomatic hypogonadism in the aging population, as well as to discuss the benefits, risks, and controversies of TRT for this unique patient population.
Etiologies of hypogonadism in aging men
Testosterone has a critical role in the modulation of adult male reproductive health, sexual function, bone health, fat metabolism, and muscle mass and strength. Testosterone production by testicular Leydig cells is closely regulated by the hypothalamic-pituitary-gonadal (HPG) axis via production of luteinizing hormone (LH) . Failure in this delicate balance can result in primary, secondary, or mixed hypogonadism. Once produced, testosterone circulates systemically either protein bound or unbound. Approximately 20-25% is loosely protein bound to albumin and can uncouple to join free serum testosterone (1-2%), making 'bioavailable' free testosterone [Manni et al. 1985] . The remainder is tightly protein bound by sex hormone-binding globulin (SHBG) and is physiologically inactive [Rosner, 1991] . Biologically active testosterone can then bind androgen-binding protein within Sertoli cells to maintain intratesticular testosterone for spermatogenesis [Jarow et al. 2001 ], convert to more potent androgens in nontesticular tissue such as dihydrotestosterone via 5α-reductase enzyme, or convert to estrogen via aromatase enzyme. Testosterone, other androgens, estrogen, and inhibin from Sertoli cells all serve as negative feedback to gonadotropin secretion [Hayes et al. 2001] .
Older men can suffer from well-known causes of primary hypogonadism as seen in younger men. Primary hypogonadism is classically diagnosed by laboratory testing in symptomatic men revealing hypergonadotropic hypogonadism with low serum testosterone levels and elevated LH, suggesting testicular dysfunction or failure. Common causes of hypogonadism include: prior treatment for testicular cancer, prior testicular infection, medications with gonadotoxic effects including chemotherapy, environmental toxins, orchiectomy, trauma, idiopathic testicular atrophy, genetic aberrations such as Klinefelter's syndrome, or anatomic abnormalities such as varicoceles [McBride et al. 2015] . Varicoceles are known to cause intratesticular dysfunction and have a higher prevalence in men with increasing age [Canales et al. 2005] . Recent data have not only correlated varicoceles with low testosterone but also suggest improvement in testosterone levels with repair [Tanrikut et al. 2011] . In general, etiologies of primary hypogonadism should be considered for treatment regardless of patient age.
In contrast to primary hypogonadism, secondary hypogonadism typically presents with hypogonadotropic hypogonadism due to insufficient gonadotropin production. In addition to being associated with numerous medical conditions and medications discussed below, primary gonadotropin-releasing hormone (GNRH) deficiency such as Kallmann syndrome, hypopituitarism from prior radiation, infection, trauma, or hyperprolactinemia from pituitary adenomas can all cause secondary hypogonadism and should be considered for treatment.
In aging men, the predominant form of testosterone deficiency (TD) is mixed with primary and secondary hypogonadism components, due to several reasons. LH levels can vary in older men based upon decreased numbers and function of Leydig cells, decreased sensitivity of the HPG axis to feedback inhibition, and/or decreased LH pulse amplitude despite normal pulse frequency. Decreased LH pulse amplitude may potentially be related to reductions in neuronal cell secretion of GNRH [Vermeulen and Kaufman, 1995; Kaufman and Vermeulen, 2005] . Total serum testosterone levels also decrease with age, but the greatest decrease is seen with bioavailable testosterone, which can be reduced by 50% by age 75 [Vermeulen et al. 1996 ]. This fall in bioavailable testosterone is due to rising SHBG levels with aging, which explains the disproportion between total and bioavailable testosterone levels. In addition to aging, SHBG levels are also increased with chronic disease states such as hyperthyroidism, cirrhosis, and HIV. Diurnal variation in testosterone levels related to pulsatile release of gonadotropins by the HPG axis results in peak serum testosterone levels during morning hours. Aging can blunt diurnal variation [Bremner et al. 1983 ], but fluctuating serum testosterone levels can also be affected by laboratory assay differences in sensitivity, seasonality, triglyceride levels, glucose ingestion, or activity prior to serum laboratory draw Paduch et al. 2014 ]. However, a proportion of older men with low afternoon testosterone levels can have normal morning levels [Brambilla et al. 2007; Crawford et al. 2007] .
A number of possible comorbid medical conditions may accentuate these age-related, physiologic alterations in serum testosterone levels resulting in secondary or mixed hypogonadism. It is important in the current medical climate for the clinician to identify a contributing pathologic etiology other than only age-related decreases in serum testosterone to warrant treatment. MetS, defined by the International Diabetes Federation as central obesity, hypertriglyceridemia, low high-density lipid cholesterol, hypertension, or insulin resistance, has been highly associated with TD and low SHBG levels [Cunningham, 2015] , in up to 50-70% of patients [Vermeulen et al. 1993; Wu et al. 2010] . Possible underlying mechanisms include hyperinsulinemia causing suppression of SHBG synthesis [Hautanen, 2000] , hyperleptinemia-mediated inhibition of the HPG axis [Isidori et al. 1999 ], hyperestrogenemia-mediated gonadotropin inhibition [Maggio et al. 2010] , and circulating inflammatory cytokine inhibition of Leydig-cell function [Bornstein et al. 2004] . In fact, a recent meta-analysis including four prospective studies demonstrated that TD is associated with a three-to four-fold increased risk of diabetes mellitus, which is a known predictor of cardiovascular morbidity and mortality [Brand et al. 2014] . Current data suggest improvement in components of MetS with TRT, but large, placebo-controlled trials are lacking [Cunningham, 2015] .
Chronic obstructive pulmonary disease and obstructive sleep apnea (OSA) have both been associated with TD with proposed mechanisms including hypercapnia, hypoxia, and in the case of OSA, sleep fragmentation-mediated dysregulation of diurnal hypothalamic rhythms that can improve with underlying disease treatment [Aasebo et al. 1993; Luboshitzky et al. 2002] . Chronic liver disease and/or alcoholism can alter hepatic SHBG production and affect the HPG axis centrally via hyperestrogenemia-mediated effects, whereas alcohol has additional, gonadotoxic effects [Bannister et al. 1987; Emanuele and Emanuele, 1998 ]. Hypothyroidism symptoms can mimic some symptoms of hypogonadism and should be considered as part of the evaluation despite ongoing controversy over normal thyroidstimulating hormone (TSH) levels in older men [Boucai et al. 2011; Bremner et al. 2012] . Other medical conditions associated with TD in older men include acute illness, rheumatoid arthritis, chronic kidney disease, HIV with or without AIDS, hemochromatosis, and depression, all via multifactorial mechanisms [Kelly et al. 1984; Woolf et al. 1985; Kalyani et al. 2007; Khera et al. 2012 ]. TD has also been associated with erectile dysfunction (ED) and Peyronie's disease (PD), the latter of which is controversial [Nam et al. 2011; Cavallini et al. 2012; Isidori et al. 2014] . PD tends to occur in the same population as TD, and data have shown that TD leads to upregulation of transforming growth factor beta, resulting in corporal fibrosis [Traish and Guay, 2006 ], which can be reversed with TRT in animal models [Traish et al. 1999 ]. Yet, a recent, large, retrospective review found that men presenting with either PD or ED have a similar incidence of TD, suggesting the high rate of low testosterone in men with PD may be related more to the underlying sexual dysfunction [Kirby et al. 2015] .
Several medications frequently prescribed in older men may also contribute to the development of TD. The frequently prescribed 5α-reductase inhibitors for prostate enlargement can induce mild hypogonadal symptoms [Thompson et al. 2003 ]. Many cancer treatments, such as alkylating agents, can significantly harm Leydig-cell function and spermatogenesis [Howell et al. 2001 ]. Systemic glucocorticoids have direct inhibitory effects on all levels of the HPG axis, which can persist up to 12 months after cessation of therapy [Morrison et al. 1994] . Similarly, any previous lifetime exposure to exogenous anabolic steroids or prior TRT can negatively impact the HPG axis for up to 2-3 years and even permanently in some cases [Jarow and Lipshultz, 1990; Coward et al. 2013] . Increasingly common, opioid analgesics can suppress the HPG axis centrally and peripherally, but the effects are short lived depending upon the half-life of agent used [Rajagopal et al. 2004; Katz and Mazer, 2009 ]. Commonly used antihypertensive (β-blockers) and anticholesterol (statins) medications can induce mild to moderate reductions in serum testosterone levels [Rosen et al. 1988; Schooling et al. 2013] . Whether the medication, underlying medical condition, or both are at fault is unclear, but TD and comorbid medical conditions, and associated treatments can lead to a self-reinforcing cycle and development of TD symptoms.
Diagnosis
The diagnosis of TD in aging men is based upon the presence of both clinical symptoms and low serum testosterone levels similar to the approach used in younger or middle-aged men [Bhasin et al. 2010; Buvat et al. 2010] , because high-quality, randomized trials are lacking in older men. Yet the diagnosis of TD in older men is more difficult due to the preponderance of symptoms associated with normal aging that overlap with those associated with TD. However, evaluating patients for biochemical TD alone can lead to significant over-diagnosis due to the clear agerelated decrease in testosterone levels [Tajar et al. 2012 ]. In fact, many older men with 'low testosterone' are asymptomatic [Wu et al. 2010] . This dilemma has led many large medical societies and organizations to define the phenomenon of LOH as a 'clinical and biochemical syndrome associated with advancing age and characterized by symptoms and a deficiency in serum testosterone levels below those seen in young healthy males' [Wang et al. 2009 ]. For these reasons, defined etiologies of primary and secondary symptomatic hypogonadism must be differentiated from LOH during the initial evaluation; otherwise the apparent low testosterone may be a normal physiologic response with aging.
Clinical diagnosis
The majority of clinical symptoms associated with hypogonadism in aging men can be categorized as sexual or nonsexual. Sexual symptoms include decreased libido, decreased frequency of sexual thoughts, decreased frequency or rigidity of nocturnal erections, and ED [Morelli et al. 2007; Corona et al. 2014] . Nonsexual symptoms include fatigue, decreased energy, poor concentration, decreased sense of well-being, depressed mood, decreased vitality, and depression [Bhasin et al. 2010; Buvat et al. 2010] . Additional signs often associated with symptomatic hypogonadism include obesity, decreased muscle mass and strength, decreased bone-mineral density (BMD) and osteoporosis, hot flashes, and mild anemia [Dohle et al. 2012 ]. Physical examination is usually nonspecific but can reveal testicular atrophy or asymmetry, varicoceles, penile plaques or other abnormalities, decreased pubic hair, gynecomastia, visceral obesity, and diminished prostate volume, although some men with TD maintain an enlarged prostate [Corona et al. 2009 ]. Many of these signs and symptoms are nonspecific. Sexual symptoms, particularly decreased libido, have been shown to strongly correlate with serum testosterone levels [Travison et al. 2006; Corona et al. 2009 ]. Overall, the use of symptom questionnaires for screening or diagnosis is not encouraged due to poor specificity (30-40%), however the quantitative Androgen Deficiency in the Aging Male and the Aging Males' Symptoms questionnaires demonstrate higher sensitivities at 97% and 83%, respectively, and are utilized in some centers of excellence Wang et al. 2009; Mohamed et al. 2010] . In addition, the ANDROTEST-structured interview is a useful clinical adjunct for screening in men with sexual dysfunction [Corona et al. 2006 ].
Laboratory diagnosis
In aging men who present with signs or symptoms of hypogonadism, the diagnosis must be confirmed with laboratory testing. Initial testing should include a total serum testosterone level drawn between 7 am and 11 am [Diver et al. 2003 ], due to diurnal variation. However, blunting of diurnal variation can occur in a significant proportion of older men [Crawford et al. 2007] , and up to 30% of men with initially abnormal values will have normal levels on repeat testing [Brambilla et al. 2007 ]. As such, most experts agree that a second, confirmatory level should be obtained [Wang et al. 2009; Bhasin et al. 2010] . What constitutes a 'normal value' has not been clearly established in older men due to multiple issues including underlying physiologic complexity as previously discussed and inherent variations in laboratory testing. Laboratory techniques that provide good precision and accuracy are either radioimmunoassay or mass spectrometry, but their use is not standardized [Paduch et al. 2014] . Most laboratories and experts consider 10-12 nmol/l as the lower limit of normal based upon data from younger men [Wang et al. 2009; Bhasin et al. 2010; Buvat et al. 2010; Dohle et al. 2012 ]. However, some data suggest a more consistent manifestation of symptoms, and benefit from treatment, at levels below 6.4-8.0 nmol/l, particularly in older men [Wang et al. 2009; Yeap et al. 2012] . Recent data from the European Male Aging Study (EMAS) group correlating serum testosterone levels with 32 different hypogonadal symptoms in older men demonstrated different symptoms appear at different testosterone levels, but only with sexual symptoms (ED, low libido, and decreased nocturnal erections) was a continuous inverse relationship with serum testosterone levels statistically significant [Wu et al. 2010 ]. In addition, they found a five-fold and three-fold increased risk of death in men with severe TD and sexual dysfunction [Pye et al. 2014 ]. These findings lead to the proposal of diagnostic criteria for symptomatic hypogonadism to include the presence of three sexual symptoms combined with a total testosterone level lower than 11 nmol/l or free testosterone lower than 220 pmol/l in those with equivocal total testosterone levels (8-11 nmol/l). Using these authors' strict criteria, only approximately 5% of men older than 70 years have hypogonadism, which is less than in other studies reporting up to 12% using less strict criteria [Araujo et al. 2004 [Araujo et al. , 2007 . However, the EMAS group excluded men already diagnosed and treated, and their study population's mean body mass index (BMI) was 27 with a low rate of MetS likely not representative of the general population where rates of TD may be higher. It is known that older men often under report sexual symptoms due to embarrassment or misinterpretation as 'normal aging ' [Baldwin et al. 2003 ]. Overall, in aging men, the exact total testosterone threshold below which symptoms ensue and treatment should initiate is unclear, and rigid thresholds should thus not be used [Wu et al. 2010] . Therefore, some experts recommend treatment for clearly symptomatic men even if serum testosterone levels are 'low-normal' and free testosterone levels are low ].
With such ambiguity in what constitutes 'normal', many clinicians will routinely determine free testosterone levels, with levels lower than 220-345 pmol/l considered abnormal. Equilibrium dialysis is the gold standard, but is expensive, complex, and commonly unavailable at most laboratories Lunenfeld et al. 2015 ]. An alternative is the Vermeulen calculation method, utilizing total testosterone, SHBG, and albumin levels [Vermeulen et al. 1999] . SHBG is particularly important to help interpret total testosterone levels in older men due to its variability based upon associated comorbidities. Some data demonstrate interindividual variation in androgenreceptor sensitivity due to cysteine adenine guanine (CAG) polymorphisms, explaining the presence of symptoms in the absence of 'low' testosterone levels [Rajender et al. 2007; Zitzmann, 2009] . Accordingly, some clinicians incorporate CAG evaluation in their diagnostic armamentarium . Serum gonadotropins (follicle-stimulating hormone and LH) are also helpful in distinguishing primary, secondary, and compensated hypogonadism, which can be difficult in older men with multiple comorbidities and medications that manipulate the HPG axis. Compensated hypogonadism is defined as low-normal testosterone (> 10 nmol/l), elevated LH (> 9.4 IU/l), and physical symptoms. It is common in older men and often progresses to more fulminant primary hypogonadism and need for treatment ]. In addition, serum prolactin, TSH, vitamin D, and estrogen levels are helpful in elucidating underlying etiologies, with the latter useful to calculate the testosterone:estrogen ratio [Bunch et al. 2002; Corona et al. 2007; McBride et al. 2015] . Assessment of other physical manifestations of hypogonadism, particularly in those with near castrate levels, should be considered, specifically, anemia and bone-density assessments, as these can improve with treatment [Snyder et al. 1999; Tajar et al. 2012; Hoppe et al. 2013; Spitzer et al. 2013 ].
Treatment
Benefits TRT has the theoretical potential to improve many of the physiologic manifestations of deficiency. In general, the benefit of treatment for hypogonadism in older men is unclear due to lack of randomized controlled trials and other quality data. Sexual symptoms highly correlate with hypogonadism, yet data from interventional studies demonstrating improvement with treatment are unclear. Normal erections can occur in aging hypogonadal men, and increasing testosterone levels do not necessarily improve ED symptoms [Rhoden et al. 2002] . Likewise, mean serum testosterone levels in men with ED are often in the 'normal range' [Corona et al. 2004] . Two different meta-analyses agreed that TRT can improve libido, nocturnal erections, and sexual satisfaction, but the effect in older men is inconsistent and fades with time [Isidori et al. 2005; Bolona et al. 2007] . A more recent meta-analysis confirmed this but identified publication bias between industry-sponsored and unsponsored trials of TRT for LOH, explaining previously stated inconsistencies .
There is also a potential benefit of combining TRT with phosphodiesterase-5 inhibitors (PDE5Is) in hypogonadal men with ED symptoms. In hypogonadal men with symptoms of ED initially treated successfully with PDE5Is alone, further benefit by adding TRT has not been demonstrated [Spitzer et al. 2012] . However, in hypogonadal men with ED symptoms that do not experience satisfactory improvement with PDE5Is alone, TRT has been shown to 'salvage' these men as PDE5I-treatment failures, particularly when serum testosterone levels are lower than 10 nmol/l . This was also confirmed in a recent meta-analysis . Endocrine society guidelines [Bhasin et al. 2010] recommend offering TRT to men with low testosterone levels and low libido or ED, and in addition to PDE5I-treatment failures. In the context of the recent FDA statement, to support TRT in men with ED or low libido, clinicians should also identify an underlying etiology for symptomatic hypogonadism of which ED or low libido are a symptom.
Data associating age-related hypogonadism and risk for falls, reduced strength, muscle mass, physical performance, and frailty are available [Schaap et al. 2005; Krasnoff et al. 2010] . Some of these physical parameters, such as grip strength and muscle mass, can improve with TRT in healthy older men [Srinivas-Shankar et al. 2010; Hildreth et al. 2013] . However improvement in clinically significant physical function and performance-based measures in older men is less robust [Page et al. 2005; Storer et al. 2008; Srinivas-Shankar et al. 2010] , and effects are often short lived [O'Connell et al. 2011] . Men with LOH are at risk for decreases in BMD and osteoporosis, and treatment may mitigate the risk. A few randomized studies mostly using injectable testosterone formulations have shown an improvement in lumbar and hip BMD, the latter of which is considered by some to reflect fracture risk [Amory et al. 2004; Aversa et al. 2012 ]. Yet a meta-analysis of quality studies only demonstrated improvements in lumber BMD [Tracz et al. 2006] , and no studies to date have evaluated fracture risk. As mentioned, data demonstrating definitive improvement in obesity, diabetes, and/or MetS are not yet available, but several studies suggest improvements in obesity, waist circumference, insulin sensitivity, and diabetes parameters using various testosterone formulations [Heufelder et al. 2009; Cai et al. 2014; Hackett et al. 2014] . Conversely, other reports failed to demonstrate such findings [Jones et al. 2011; Gianatti et al. 2014; Traish, 2014] . Lastly, sparse data supporting improvements in depression [Giltay et al. 2010; Pope et al. 2010], and cognition [Azad et al. 2003; Cherrier et al. 2005] , are suggestive of benefit but further research is needed.
Controversies and risk
TRT is generally considered a safe and effective treatment for TD in younger and middle-aged men, but the same may not be true for older hypogonadal men. Aging men inherently experience exaggerated treatment side effects due to reduced capacity to metabolize testosterone and higher burden of comorbid disease [Coviello et al. 2006 ]. Higher rates of erythrocytosis are seen in older men [Calof et al. 2005; Coviello et al. 2008] , with some data suggesting the upper limit of safe levels may be lower in older men with various comorbidities [Gagnon et al. 1994; Danesh et al. 2000 ]. Men who desire to maintain their fertility should not be given exogenous testosterone without discussion of the negative effects on spermatogenesis and the inherent delay in recovery of spermatogenesis after treatment cessation, which in some cases is not spontaneous and may require additional medical treatment. In addition, any man with a history of breast cancer should not receive TRT, and all men undergoing treatment should be counseled regarding this rare but potential risk with long-term TRT [Medras et al. 2006 ].
Similarly, prostate cancer has historically been a contraindication to TRT with caution reflected in most guideline statements [Wang et al. 2009; Bhasin et al. 2010; Buvat et al. 2010; Dohle et al. 2012 ]. More recently, the 'saturation model' emerged [Morgentaler and Traish, 2009] , establishing that prostate tissue, benign or malignant, is only sensitive to serum levels of testosterone below a certain threshold, above which prostate tissue behaves irrespective of androgen levels. Other data have confirmed these findings and propose a threshold level of approximately 8.6 mmol/l [Rastrelli et al. 2013] . Several studies also support the use of testosterone in men 'at risk' for prostate cancer without increasing their baseline odds of prostate cancer development [Roddam et al. 2008; Muller et al. 2012; Cui et al. 2014 ]. Yet the absence of large, long-term randomized controlled trials precludes a definitive answer and at-risk men should be appropriately screened for prostate cancer prior to initiation of, and at regular intervals, during treatment. A slight increase in prostate-specific antigen (PSA) can be expected with treatment initiation, particularly in severely hypogonadal males (< 8.6 mmol/l), which is usually modest (< 0.01 mmol/l) within the first 6 months of therapy [Bhasin et al. 2003 ]. Some clinical guidelines suggest waiting to check a serum PSA until after 6 months of treatment to allow for such physiologic changes [Dohle et al. 2012 ]. However, a PSA rise greater than 0.06 mmol/l within 18 months of therapy may indicate underlying, undiagnosed prostate cancer [Coward et al. 2009 ]. In such cases, one should consider continuing TRT until underlying prostate cancer is confirmed because the many causes of hypogonadism, such as MetS, may have a greater mortality risk than prostate cancer that can potentially be mitigated by TRT.
In addition, a growing body of data demonstrates the safety of TRT in men with definitively treated, localized, low-to-intermediate risk (Gleason 6 or 7) prostate cancer biochemically free of recurrence 1-2 years after treatment with surgery [Kaufman and Graydon, 2004; Agarwal and Oefelein, 2005; Khera et al. 2009; Pastuszak et al. 2013a] , or radiation [Morales et al. 2009; Pastuszak et al. 2013b; Balbontin et al. 2014] . Likewise, limited reports of testosterone use in hypogonadal men on active surveillance protocols appear promising [Morales, 2011; Morgentaler et al. 2011 ]. Yet one must emphasize the data for TRT in men with a history of prostate cancer are without randomized or placebo controlled trials and should be interpreted with caution. Historically a contraindication to treatment, TRT use in the setting of benign prostatic hyperplasia (BPH) is now considered safe with no data demonstrating exacerbation of symptoms with treatment [Calof et al. 2005] , and in fact some suggesting improvement in lower urinary tract symptoms for those with LOH and BPH [Shigehara et al. 2011; Yassin et al. 2014 ].
More controversial is the relationship between TRT, CVD, and mortality. Historically, low serum testosterone levels have been associated with increases in several known risk factors for CVD including C-reactive protein, carotid intima media thickness, interleukin-1β, BMI, blood pressure, lipid levels, and coagulation profiles [Muller et al. 2004; Nettleship et al. 2007; Aversa et al. 2010; Kaplan et al. 2010] . Likewise several large population-based and observational studies have established an inverse relationship between serum testosterone levels and risk of developing CVD and CVD-related or diabetes-related mortality [Khaw et al. 2007; Corona et al. 2010; Ohlsson et al. 2011; Haring et al. 2013; Muraleedharan et al. 2013] . A few meta-analyses have shown no increase in cardiovascular adverse effects or mortality with TRT [Calof et al. 2005; Fernandez-Balsells et al. 2010; Carson and Rosano, 2012] . In addition, recent, large retrospective studies have suggested TRT in aging hypogonadal men can improve overall mortality [Shores et al. 2012; Muraleedharan et al. 2013 ]. Yet to date there are no randomized trials or other high-quality data to validate these findings. In fact, more recently, a handful of studies assert potentially worse cardiovascular events and mortality in older hypogonadal men on TRT [Basaria et al. 2010; Vigen et al. 2013; Xu et al. 2013; Finkle et al. 2014] . These data contain several design flaws and questionable statistics, leading to well-publicized controversy [Morgentaler et al. 2015; Sigman, 2015] .
Nonetheless, the FDA reviewed the current data on TRT in men with LOH in March 2015 and determined that the benefit and safety of testosterone use in these men have not been established, and required amending manufacturer labels to reflect the possibility of increased risk for heart attack or stroke with treatment. Their conclusion statement regarding CVD is the 'signal of cardiovascular risk is weak and only a prospective, well-controlled clinical trial could determine whether testosterone causes cardiovascular harm'. Moreover, the FDA report states: 'The benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man's symptoms seem related to low testosterone', which the FDA recommended be added to manufacturer labels for testosterone products. Lastly, the statement indicated that exogenous testosterone should not be used for hypogonadism without a 'defined cause' considered to be a 'disorder of the testicles, pituitary gland, or brain resulting in hypogonadism'. Since the FDA statement, the American Association of Clinical Endocrinologists (AACE) released a position statement acknowledging the 'weak signal' for cardiovascular risk with TRT and stated that 'there is no compelling evidence that testosterone therapy either increases or decreases cardiovascular risk' [Goodman et al. 2015 ]. Furthermore, the AACE statement indicates that 'men with unequivocally low total and/or free testosterone after thorough diagnostic workup should be considered for TRT and extra caution should be exercised in the frail elderly'. Bolstering the AACE recommendations is a very recent, retrospective review of over 80,000 veterans demonstrating a statistically significant reduction in all-cause mortality, myocardial infarction and stroke in those with normalization of total testosterone levels with TRT [Sharma et al. 2015] . Ultimately, in the context of the FDA statement, the distinction of exactly which 'disorders' result in dysfunction of the testicles, pituitary gland, or brain to the clinician. The future burden will be on clinicians to clearly identify and document any and all medical conditions that physiologically explain a patient's symptomatic primary, secondary, or mixed hypogonadism to justify treatment.
Conclusion
As testosterone use continues to rise along with the increased recognition and prevalence of hypogonadism in the aging male population, the temptation for treatment with TRT in older men will continue to persist for providers and patients alike. It is important that clinicians understand the complex, underlying physiology and strong association with many chronic medical conditions and medications in order to appreciate fully the difficulty in diagnosis. Even in older men who meet diagnostic criteria for LOH, the benefit of treatment in this setting alone is not clear and may be associated with negative impacts on cardiovascular health or mortality. To the contrary, for men with identifiable etiologies or primary or secondary hypogonadism, treatment may be warranted regardless of age.
The authors encourage clinicians to only offer TRT to men diagnosed with symptomatic hypogonadism based upon a careful history demonstrating clear symptoms along with convincing laboratory data, and only after a thorough discussion of the uncertain benefits and possible risks of treatment. Informing patients of the recent FDA statement regarding TRT in aging men is of utmost importance in the current healthcare climate, particularly because testosterone use for this population may now be considered 'off-label'. With these caveats, the authors also want to reiterate the vast literature of known and proven benefits of testosterone normalization, which must also be carefully considered during the decision of whether or not to offer treatment. The best approach to TRT for the population of older hypogonadal men is probably one of full disclosure and shared decision-making.
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